<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bionxt Solutions Inc. (formerly Was Xphy/xphyto Therapeutics Corp. Until 2022-11-11) — News on 6ix</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11</link>
<description>Latest news and press releases for Bionxt Solutions Inc. (formerly Was Xphy/xphyto Therapeutics Corp. Until 2022-11-11) on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 07:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11" rel="self" type="application/rss+xml" />
<item>
<title>BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-signs-strategic-agreement-for-eurasian-commercialization-following-cladribine-odf-patent-grant-in-eurasia-and-europe</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-signs-strategic-agreement-for-eurasian-commercialization-following-cladribine-odf-patent-grant-in-eurasia-and-europe</guid>
<pubDate>Tue, 17 Mar 2026 07:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has signed ...</description>
</item>
<item>
<title>BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-receives-milestone-epo-decision-080500885</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-receives-milestone-epo-decision-080500885</guid>
<pubDate>Tue, 17 Feb 2026 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European ...</description>
</item>
<item>
<title>BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-secures-innovative-chaperone-technology-080500110</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-secures-innovative-chaperone-technology-080500110</guid>
<pubDate>Thu, 05 Feb 2026 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, today announced the signing of a non-binding ...</description>
</item>
<item>
<title>BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-accelerates-odf-multiple-sclerosis-080500730</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-accelerates-odf-multiple-sclerosis-080500730</guid>
<pubDate>Mon, 26 Jan 2026 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce significant progress ...</description>
</item>
<item>
<title>BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-final-preclinical-results-080500307</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-final-preclinical-results-080500307</guid>
<pubDate>Wed, 21 Jan 2026 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig study demonstrating that its proprietary needle-free, ...</description>
</item>
<item>
<title>BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-successful-final-vivo-080500712</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-successful-final-vivo-080500712</guid>
<pubDate>Mon, 19 Jan 2026 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has completed ...</description>
</item>
<item>
<title>Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/over-40-adults-struggle-swallow-080500315</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/over-40-adults-struggle-swallow-080500315</guid>
<pubDate>Wed, 17 Dec 2025 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce significant progress ...</description>
</item>
<item>
<title>BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-advances-melt-mouth-cladribine-080500957</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-advances-melt-mouth-cladribine-080500957</guid>
<pubDate>Tue, 09 Dec 2025 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's ...</description>
</item>
<item>
<title>BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-signs-letter-agreement-acquire-080500297</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-signs-letter-agreement-acquire-080500297</guid>
<pubDate>Mon, 01 Dec 2025 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce it has signed a ...</description>
</item>
<item>
<title>BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-secures-final-patent-grant-080500698</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-secures-final-patent-grant-080500698</guid>
<pubDate>Thu, 20 Nov 2025 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / November 20, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian ...</description>
</item>
<item>
<title>BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-intention-grant-patent-080500975</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-intention-grant-patent-080500975</guid>
<pubDate>Tue, 04 Nov 2025 08:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / November 4, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has received an "Intention ...</description>
</item>
<item>
<title>BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-readiness-grant-patent-070500067</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-readiness-grant-patent-070500067</guid>
<pubDate>Thu, 30 Oct 2025 07:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 30, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian ...</description>
</item>
<item>
<title>BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-enters-the-final-stretch-before-human-trials-for-next-generation-ms-drug</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-enters-the-final-stretch-before-human-trials-for-next-generation-ms-drug</guid>
<pubDate>Thu, 23 Oct 2025 09:29:00 GMT</pubDate>
<description>BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead product BNT23001, a proprietary sublingual Cladribine formulation for the treatment of multiple sclerosis (MS).</description>
</item>
<item>
<title>BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-launches-15-day-sublingual-070500871</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-launches-15-day-sublingual-070500871</guid>
<pubDate>Tue, 21 Oct 2025 07:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, is pleased to announce the ...</description>
</item>
<item>
<title>BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-solutions-provides-annual-general-235000263</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-solutions-provides-annual-general-235000263</guid>
<pubDate>Thu, 09 Oct 2025 23:50:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) wishes to advise its shareholders, due to the Canada Post mail strike, of alternative ways to vote their shares ...</description>
</item>
<item>
<title>BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-completes-fast-track-us-070500976</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-completes-fast-track-us-070500976</guid>
<pubDate>Thu, 09 Oct 2025 07:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today announced that it has ...</description>
</item>
<item>
<title>BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-targeted-chemotherapy-drug-070500562</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-targeted-chemotherapy-drug-070500562</guid>
<pubDate>Thu, 02 Oct 2025 07:05:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / October 2, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased to ...</description>
</item>
<item>
<title>BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-sublingual-cladribine-multiple-070500963</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-reports-sublingual-cladribine-multiple-070500963</guid>
<pubDate>Mon, 29 Sep 2025 07:05:00 GMT</pubDate>
<description>VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to provide an update on ...</description>
</item>
<item>
<title>BioNxt Solutions Announces Closing of Shares for Debt Settlement</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-solutions-announces-closing-shares-014500587</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/bionxt-solutions-announces-closing-shares-014500587</guid>
<pubDate>Sat, 20 Sep 2025 01:45:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement ...</description>
</item>
<item>
<title>Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals</title>
<link>https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/terry-lynch-continues-capital-markets-233000320</link>
<guid isPermaLink="true">https://6ix.com/company/bionxt-solutions-inc-formerly-was-xphyxphyto-therapeutics-corp-until-2022-11-11/news/terry-lynch-continues-capital-markets-233000320</guid>
<pubDate>Fri, 19 Sep 2025 23:30:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic Mines Inc. (TSX-V: PNPN), will continue his role ...</description>
</item>
</channel>
</rss>